Vinorelbine treatment of recurrent salivary gland carcinomas

Twenty patients (13 males, females, median age 61 years, range 27-64) with recurrent adenocarcinoma-like tumors of major (10 patients) and minor (10 patients) salivary gland origin (13 adenoid cystic carcinoma, 5 adenocarcinoma, 1 malignant mixed tumor, 1 undifferentiated carcinoma) were treated with vinorelbine at the dose of 30 mg/m² IV weekly. Sixteen patients had been previously treated with surgery + radiation, 3 with surgery + radiotherapy + Novantrone® and 1 with radiotherapy alone. Nine patients had local recurrence, 2 local relapse + metastasis and 9 metastasis alone. Site of metastases are: lung (7), bone (1), lung + bone (2), lung + bone + lymph- node + skin (1). Overall 174 courses were given (median 9, range 6-19). Responses were: PR in 4 patients (200%) with a median duration of 6 months (3-9), 9 NC (45%) with a median duration of 3.5 months and 7 PD (35%). The median survival time was 10 months for PR/NC patients, 4 months for non- responders. Median overall survival was 7 months. Vinorelbine has a moderate activity in these very advanced cases.